Experienced in Heterozygous Familial Hypercholesterolemia (HeFH)

Dr. Marc S. Jacobson

Adolescent Medicine | Pediatrics
1500 N Wilmot Rd Ste B250, 
Tucson, AZ 
Accepting New Patients
Offers Telehealth
Experienced in Heterozygous Familial Hypercholesterolemia (HeFH)
1500 N Wilmot Rd Ste B250, 
Tucson, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marc Jacobson is an Adolescent Medicine specialist and a Pediatrics provider in Tucson, Arizona. Dr. Jacobson is rated as an Experienced provider by MediFind in the treatment of Heterozygous Familial Hypercholesterolemia (HeFH). His top areas of expertise are Anorexia, Obesity in Children, and Heterozygous Familial Hypercholesterolemia (HeFH). Dr. Jacobson is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Heterozygous Familial Hypercholesterolemia (HeFH).

Specialties
Adolescent Medicine
Pediatrics
Licenses
Pediatrics in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

1500 N Wilmot Rd Ste B250, Tucson, AZ 85712

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-16)
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-16)
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drug: Inclisiran
Study Phase: Phase 3
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Inclisiran
Study Phase: Phase 3
View 1 Less Clinical Trial

8 Total Publications

Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors.
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors.
Journal: Current atherosclerosis reports
Published: July 02, 2023
Similar Doctors
Advanced in Heterozygous Familial Hypercholesterolemia (HeFH)
Dr. Stanley J. Goldberg
Pediatric Cardiology | Cardiology | Pediatrics
Advanced in Heterozygous Familial Hypercholesterolemia (HeFH)
Dr. Stanley J. Goldberg
Pediatric Cardiology | Cardiology | Pediatrics

Old Pueblo Cardiology PC

3955 E Fort Lowell Rd, Suite 113, 
Tucson, AZ 
 (1.5 miles away)
520-323-7277
Languages Spoken:
English
See accepted insurances

Stanley Goldberg is a Pediatric Cardiologist and a Cardiologist in Tucson, Arizona. Dr. Goldberg is rated as an Advanced provider by MediFind in the treatment of Heterozygous Familial Hypercholesterolemia (HeFH). His top areas of expertise are Familial Hypertriglyceridemia, Defective Apolipoprotein B-100, Hyperlipoproteinemia Type 4, Heterozygous Familial Hypercholesterolemia (HeFH), and Carotid Artery Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jacobson's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile